Cencora Inc 2024年度报告

Table ofcontents 03About Cencora05CEO letter13Financial highlights14Management team15Board of Directors16GAAP/Non-GAAP financial measures18Corporate information Cencora is a leading global pharmaceutical solutionsorganization centered on improving the lives of peopleand animals around the world. We partner withpharmaceutical innovators across the value chain tofacilitate and optimize market access to therapies.Care providers depend on us for the secure, reliabledelivery of pharmaceuticals, healthcare products,and solutions. AboutCencora To our shareholders It is an honor to be the President and CEO ofCencora. Thank you to the Board of Directors fortheir trust and to Steve Collis for the seamlesshand-off and ongoing leadership and partnershipas Executive Chairman of the Board. Since assumingthe role of President and CEO of Cencora on October1, 2024, I have been focused on furthering thestrengths that have been key to our past successand investing to ensure we continue to be at theforefront of innovation and advance our ability toleverage data and analytics. We will lead with acustomer-centric approach, take on an enterprise-powered mindset and focus on innovation, whichwill ensure our differentiated value-propositionremains intact and accelerates our position as aleader in healthcare. We are well positioned withour foundation in pharmaceutical distribution andkey commercialization capabilities that allow us toprovide differentiated and integrated solutions. I amconfident in the continued success of Cencora andinspired by our team members’ pride in their workand deep dedication to our purpose–We are unitedin our responsibility to create healthier futures. Delivering differentiated valuethrough our global healthcarepositioning In fiscal 2024, Cencora grew its adjusted dilutedearnings per share by 15 percent to $13.76.Consolidated revenue was $294 billion, representinga 12 percent increase year-over-year, and adjustedoperating income increased by 11 percent to$3.6 billion. In fiscal 2024, Cencora delivered robust financialperformance while enhancing our value to allstakeholders by investing in our infrastructure,deepening strategic customer partnerships,leveraging data and analytics, and continuingto build on our strength in Specialty. Our U.S. Healthcare Solutions segment operatingincome grew 13 percent, showcasing the strengthof our position at the center of healthcare andpharmaceutical-centric strategy that enable us tocapitalize on the strong utilization trends that aredriven by pharmaceutical innovation. Our robustdistribution infrastructure supported increased salesof specialty products to physician practices andhealth systems, increased sales to our largestcustomers, and allowed us to capitalize on theopportunity presented as COVID-19 vaccines movedinto the commercial market. Our pharmaceutical-centric strategy andpurpose-driven culture drive our continuedoperational excellence and propel our strategicprogress to ensure we maintain best-in-classcustomer and partner relationships, remain at theforefront of innovation, and deliver efficiency to thehealthcare ecosystem and better outcomes forpatients and providers. Our International Healthcare Solutions segmentdelivered operating income growth of three percentand constant currency operating income growth ofnine percent. We benefited from increases at ourCanadian business, our higher-margin, high-growthspecialty logistics business, and ourless-than-wholly-owned Brazil full-line distributionbusiness. We simultaneously made key investmentsin our European distribution businesses’ informationtechnology infrastructure that will allow the businessto continue performing adeptly and efficientlythrough an evolving landscape. and dividends. On November 6, 2024, we alsoannounced an eight percent increase in our quarterlydividend, which reflects our ongoing commitment tomaintaining a reasonable, growing dividend. Through our global footprint and differentiatedhealthcare solutions, we are uniquely positioned tosupport partners both upstream and downstream.Our collaboration with upstream partners early inthe drug development process and into theircommercialization journey complements ourmultinational distribution business, uniquelysupporting pharmaceutical innovation and access.By doing so, we remain at the forefront of innovationand a core partner to market-leading healthcarecompanies, helping them navigate a complex globalhealthcare landscape. We generated $3.1 billion in adjusted free cash flow,allowing us to make strategic investments to furtherour positioning as a leading healthcare solutionsprovider while returning capital to shareholders.We returned $1.9 billion to shareholders through acombination of opportunistic share repurchases returned toshareholders$1.9B in adjusted freecash flow$3.1B invested in business throughcapital expenditures$487M Building on our track record ofvalue creation and laying thefoundation for our future In 2023, we made